Basics of antiemetic therapy during chemotherapy treatment
- Authors: Lepkova N.V.1,2, Egorova A.V.1, Bobrik E.N.1
-
Affiliations:
- The N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
- 12th Consultative and Diagnostic Center Ministry of Defense of the Russian Federation
- Issue: Vol 345, No 4 (2024)
- Pages: 30-33
- Section: Treatment and prophylactic issues
- URL: https://journals.eco-vector.com/0026-9050/article/view/632026
- DOI: https://doi.org/10.52424/00269050_2024_345_4_30
- ID: 632026
Cite item
Open Access
Access granted
Abstract
Nausea and vomiting are common and serious complications in the treatment of malignant neoplasms. The introduction of more effective antiemetic agents into oncological practice has made it possible to prevent the development of these adverse events completely in the vast majority of patients. Thus, modern anti-emetogenic therapy regimens make it possible to achieve a complete absence of vomiting in 70–90% of patients. Many studies have shown that antiemetic regimens are more effective in preventing vomiting, so even after achieving a complete response to antiemetic therapy, many cancer patients still experience a burdensome feeling of nausea. Thus, despite the success of modern methods, achieving absolute control not only over vomiting but also over nausea remains an unsolved problem in oncology.
Full Text
About the authors
N. V. Lepkova
The N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation; 12th Consultative and Diagnostic Center Ministry of Defense of the Russian Federation
Author for correspondence.
Email: 12kdc@mil.ru
кандидат медицинских наук
Russian Federation, Moscow; MoscowA. V. Egorova
The N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
Email: 12kdc@mil.ru
кандидат медицинских наук
Russian Federation, MoscowE. N. Bobrik
The N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
Email: 12kdc@mil.ru
Russian Federation, Moscow
References
- Владимирова Л.Ю., Гладков О.А., Когония Л.М. и др. Практические рекомендации по профилактике и лечению тошноты и рвоты у онкологических больных // Злокачественные опухоли: Практические рекомендации RUSSCO. – 2018. – Т. 8, № 3s2 (специальный выпуск). – С. 502–511.
- Владимирова Л.Ю., Гладков О.А., Королева И.А. и др. Практические рекомендации по профилактике и лечению тошноты и рвоты у онкологических больных // Злокачественные опухоли: Практические рекомендации RUSSCO. – 2022. – Т. 12, № 3s2-2. – С. 26–39.
- Aapro M., Alberts D. High-dose dexamethasone for prevention of cis-platin-induced vomiting. // Cancer Chemother. Pharmacol. – 1981. – Vol. 7, N 1. – P. 11–14.
- Craig J.B., Powell B.L. Review: The Management of Nausea and Vomiting in Clinical Oncology // The American J. of the Med. Sciences. – 1987. – Vol. 293, N 1. – P. 34–44.
- Grunberg S.M., Warr D., Gralla R.J. et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity–state of the art // Supportive Care in Cancer. – 2011. – Vol. 19, N S1. – P. 43–47.
- Hesketh P.J., Kris M.G., S.M. Grunberg S.M. et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy // J. Clin. Oncol. – 1997. – Vol. 15, N 1. – P. 103– 109.
- Jones D., Zhao F., Fisch M.J. et al. The Validity and Utility of the MD Anderson Symptom Inventory in Patients with Prostate Cancer: Evidence from the Symptom Outcomes and Practice Patterns (SOAPP) Data from the Eastern Cooperative Oncology Group // Clin. Genit. Cancer. – 2014. – Vol. 12, N 1. – P. 41–49.
- Marty M., Pouillart P., Scholl S. et al. Comparison of the 5-Hydroxytryptamine 3 (Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced Emesis // New England J. of Med. – 1990. – Vol. 322, N 12. – P. 816–821.
- Molassiotis A., Coventry P.A., Stricker C.T. et al. Validation and Psychometric Assessment of a Short Clinical Scale to Measure Chemotherapy-Induced Nausea and Vomiting: The MASCC Antiemesis Tool // JPSM. – 2007. – Vol. 34, N 2. – P. 148–159.
- Navari R.M., Aаpro M. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting // New England J. of Med. – 2016. – Vol. 374, N 14. – P. 1356–1367.
- Navari R.M., Gray S.E., Kerr A.C. Olanzapine Versus Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Randomized Phase III Trial // J. of Supportive Oncol. – 2011. – Vol. 9, N 5. – P. 188–195.
- Sanger G.J. Metoclopramide: A Template for Drug Discovery // J. Drug Discovery. – 2017. – Vol. 4, N 1. – P. 10–31.
- Zhang Z., Zhang Y., Chen G. et al. Olanzapine Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta Analysis // The Oncologist. – 2018. – Vol. 23, Iss. 5. – P. 603–616.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).